Clinical trials
Completed Behcet Syndrome trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
60 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 2 |
| 2004 | 1 |
| 2006 | 3 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 5 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 4 |
| 2017 | 4 |
| 2018 | 7 |
| 2019 | 5 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 60 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Assiut University | 6 |
| University of South Florida | 5 |
| Assistance Publique - Hôpitaux de Paris | 4 |
| Bursa Yuksek Ihtisas Training and Research Hospital | 3 |
| National Eye Institute (NEI) | 3 |
| Novartis Pharmaceuticals | 3 |
| Tehran University of Medical Sciences | 3 |
| Amgen | 2 |
| Azienda Ospedaliero-Universitaria Careggi | 2 |
| Cukurova University | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Behcet Syndrome | 60 |
| Uveitis | 9 |
| Granulomatosis with Polyangiitis | 7 |
| Takayasu Arteritis | 7 |
| Giant Cell Arteritis | 6 |
| Microscopic Polyangiitis | 6 |
| Polyarteritis Nodosa | 6 |
| Churg-Strauss Syndrome | 5 |
| IgA Vasculitis | 5 |
| Retinal Vasculitis | 5 |
Trials
Showing 26 to 50 of 60. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.